Fabryn taudin hoitomarkkinat: nykyinen analyysi ja ennuste (2023–2030)

$3999 - $6999

Antotavan painottaminen (suun kautta ja laskimoon); Hoito (substraattien pelkistysterapia, entsyymikorvaushoito, chaperone-hoito ja muut); ja alue/maa

Sivuja:

154

Taulukko:

44

Kuvio:

104

Raportin tunnus:

UMHE212562

Maantiede:

Poista valinta
  Hanki näyte
Raportin kuvaus
Sisällysluettelo
Tutkimusmenetelmät

Raportin kuvaus

Fabry Disease Treatment Market
Fabry Disease Treatment Market

Maailmanlaajuinen Fabry Disease Treatment Market was valued at USD 1.6 Billion in 2022 and is expected to grow a CAGR of 7.1% during the forecast period (2023-2030). Fabry disease treatment services mainly gained prominence due to the increased number of inherited disorders globally. Esimerkiksi, according to the Faculty of Public Health, at birth, while individually rare, collectively genetic disorders are relatively common, with a combined prevalence of around 1-2% in the UK. In addition to this, investments in healthcare departments as well as government awareness programs regarding controlling the inheritance of such neurological disorders by initiating more diagnostic tests have increased significantly in recent years, which are the key factors that are creating opportunities for the market. Many other factors were identified that helped in propelling the market in the forecast period such as the surge in government initiatives regarding genetic disorders are also driving the growth of the market. Esimerkiksi, the draft National Policy for Rare Diseases was finalized by the Government of India and placed in the public domain in January 2020 inviting views from all the stakeholders, the general public, organizations, states, and union territories.

Pfizer Inc.; Merck KGaA; Sanofi; Biocare Medical, LLC; Lilly; Teva Pharmaceutical Industries Ltd.; MITSUBISHI CHEMICAL GROUP CORPORATION; Bristol-Myers Squibb Company; GSK plc.; Bayer AG are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Raportissa esitetyt näkemykset

"Hallintotavan joukossa, suonensisäinen luokka todistaa korkeampi CAGR ennustejaksolla."

Antotavan perusteella markkinat jakautuvat suun kautta ja suonensisäisesti annettaviin segmentteihin. Suonensisäisen segmentin odotetaan kasvavan korkealla CAGR-arvolla ennustejakson aikana nopeampana toimintatapana ja tehokkuutena. Esimerkiksi mukaan Lääketieteen kirjaston helmikuussa 2023 julkaiseman artikkelin mukaan suonensisäinen lääkkeiden antotapa tarjoaa täydellisimmän lääkkeiden saatavuuden mitättömällä viiveellä. Tämä tila on myös mukava potilaille, joilla on vaikeuksia niellä lääkkeitä suun kautta. Thus, the intravenous category is expected to witness higher CAGR during the forecast period.

“Amongst treatment, chaperone treatment held a significant share in the market in 2022”

Based on treatment, the market is categorized into substrate reduction therapy, enzyme replacement therapy, chaperone treatment, and others. The chaperone treatment segment dominated the market in 2022 owing to the innovative and very safe outcomes of this therapy. Clinical data proved that oral chaperone therapy decreased and stabilized kidney function in most patients globally which is a driving factor for this segment. Owing to the above reasons, the chaperone treatment segment held a significant share of the market in the year 2022.

“Amongst regions, APAC held higher CAGR during the forecast period”

APAC is expected to grow with a high CAGR during the forecast period. Several factors such as a surge in the geriatric population in the region, the development of a wide range of therapeutics with Fabry disease treatment, and enhanced accessibility of pharmaceutical products are driving the market’s growth during the forecast period. Further, the increase in incidences of inherited neurological disorders in several parts of the region, the presence of key generic pharmaceutical companies in the region, and the surge in government initiatives and special communities are also positively impacting the market’s growth. There have been significant improvisations and enhancements in fabry disease treatment in the region. For example, in November 2023, Intian Rajiv Gandhi Centre for Biotechnology announced that it would assist all districts, taluk hospitals, and family groups in Kerala to identify rare pediatric genetic diseases. Siksi APAC:n oletetaan olevan korkeampi CAGR ennustejakson aikana.

Fabry Disease Treatment Market Report Coverage

Fabry Disease Treatment Market
Fabry Disease Treatment Market

Syyt tämän raportin ostamiseen:

  • Tutkimus sisältää markkinoiden mitoitus- ja ennusteanalyysin, jonka ovat validoineet todennettuja avainalan asiantuntijoita.
  • Raportti esittelee yhdellä silmäyksellä nopean katsauksen alan yleisestä suorituskyvystä.
  • Raportti kattaa syvällisen analyysin merkittävistä alan vertaisryhmistä keskittyen ensisijaisesti tärkeimpiin yritysten taloustietoihin, tuotevalikoimaan, laajentumisstrategioihin ja viimeaikaiseen kehitykseen.
  • Yksityiskohtainen tarkastelu alan kuljettajista, rajoituksista, tärkeimmistä trendeistä ja mahdollisuuksista.
  • Tutkimus kattaa kattavasti markkinat eri segmenteillä.
  • Alan aluetason syvällinen analyysi.


Mukautusvaihtoehdot:

The global fabry disease treatment market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

Usein kysytyt kysymykset (FAQ)

Q1: What is the current market size and growth potential of the fabry disease treatment market?

Ans: The fabry disease treatment market was valued at USD 1.6 Billion in 2022 and is expected to grow a CAGR of 7.1% during the forecast period (2023-2030).

Q2: What are the driving factors for the growth of the fabry disease treatment market?

Ans. Investments in healthcare departments as well as government awareness programs regarding controlling the inheritance of such neurological disorders and rising investments in healthcare departments are the driving factors for the growth of the fabry disease treatment market.

Q3: Which segment has the largest share of the fabry disease treatment market by mode of administration?

Ans: The oral segment has the largest share of the fabry disease treatment market by mode of administration.

Q4: What are the emerging technologies and trends in the fabry disease treatment market?

Ans: New treatment methods like substrate reduction therapy and chaperone treatment are emerging technologies and trends in the fabry disease treatment market.

Q5: Which region will dominate the fabry disease treatment market?

V: Pohjois-Amerikan odotetaan hallitsevan markkinoita ennustejaksolla.

Q6: Who are the key players operating in the fabry disease treatment market?

Ans: Pfizer Inc.; Merck KGaA; Sanofi; Biocare Medical, LLC; Lilly; Teva Pharmaceutical Industries Ltd.; MITSUBISHI CHEMICAL GROUP CORPORATION; Bristol-Myers Squibb Company; GSK plc.; Bayer AG are the key players operating in the fabry disease treatment market.

Voit myös ostaa osia tästä raportista. Haluatko tarkistaa osan viisaasti
hinta lista?

1.1.Markkinoiden määritelmät
1.2.Päätavoite
1.3.Sidosryhmät
1.4.rajoitus

 

2.1.Research Process of the Fabry Disease Treatment Market
2.2.Research Methodology of the Fabry Disease Treatment Market
2.3.Vastaajan profiili

 

3MARKKINASYNOPSIS
4TIIVISTELMÄ
5IMPACT OF COVID-19 ON THE FABRY DISEASE TREATMENT MARKET

 

6FABRY DISEASE TREATMENT MARKET REVENUE (USD BN), 2020-2030F

 

7.1.Oraalinen
7.2.suonensisäinen

 

8.1.Substrate Reduction Therapy
8.2.Entsyymikorvaushoito
8.3.Chaperone Treatment
8.4.Muuta

 

9.1.Pohjois-Amerikka   
 9.1.1.USA 
 9.1.2.Kanada 
 9.1.3.Muu Pohjois-Amerikka
9.2.Eurooppa   
 9.2.1.Saksa 
 9.2.2.UK 
 9.2.3.Ranska 
 9.2.4.Italia 
 9.2.5.Espanja 
 9.2.6.Muu Eurooppa
9.3.Aasian ja Tyynenmeren  
 9.3.1.Kiina 
 9.3.2.Japani 
 9.3.3.Intia 
 9.3.4.Muu Aasia-Tyynenmeren alue
9.4.Muu maailma  
10.1.Markkinoiden kuljettajat
10.2.Markkinahaasteet
10.3.Vaikutusanalyysi

 

11FABRY DISEASE TREATMENT MARKET OPPORTUNITIES

 

12FABRY DISEASE TREATMENT MARKET TRENDS

 

13.1.Kysyntäpuolen analyysi
13.2.Tarjontapuolen analyysi

 

14ARVOKETJUANALYYSI

 

15.1.kilpailutilanteessa
 15.1.1.Porters Fiverin joukkojen analyysi

 

16.1.Pfizer Inc.
16.2.Merck KGaA
16.3.Sanofi 
16.4.Biocare Medical, LLC 
16.5.Lilly 
16.6.Teva lääketeollisuus Oy
16.7.MITSUBISHI CHEMICAL GROUP CORPORATION 
16.8.Bristol-Myers Squibb -yhtiö 
16.9.GSK plc.  
16.10.Bayer AG 

 

17VASTUUVAPAUSLAUSEKE

 

Tutkimusmenetelmät

Research Methodology for the Fabry Disease Treatment Market Analysis (2023-2030)

Analyzing the historical market, estimating the current market, and forecasting the future market of the global fabry disease treatment market were the three major steps undertaken to create and analyze the adoption of fabry disease treatment in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global fabry disease treatment market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:

Markkinoiden historiallisen koon analyysi

Vaihe 1: Toissijaisten lähteiden perusteellinen tutkimus:

Detail secondary study was conducted to obtain the historical market size of the fabry disease treatment market through company internal sources such as vuosikertomukset ja tilinpäätökset, tulosesittelyt, lehdistötiedotteet jne., ja ulkoisista lähteistä mukaan lukien lehdet, uutiset ja artikkelit, hallituksen julkaisut, kilpailijoiden julkaisut, sektoriraportit, kolmannen osapuolen tietokannat ja muut uskottavat julkaisut.

Vaihe 2: Markkinoiden segmentointi:

After obtaining the historical market size of the fabry disease treatment market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as mode of administration, treatment, and regions. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.

Vaihe 3: tekijäanalyysi:

Hankittuamme eri segmenttien ja alasegmenttien historiallisen markkinakoon, teimme yksityiskohtaisen tekijäanalyysi to estimate the current market size of the fabry disease treatment market. Further, we conducted factor analysis using dependent and independent variables such as mode of administration, treatment, and regions of fabry disease treatment. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the fabry disease treatment market sector across the globe.

Nykyinen markkinakokoarvio ja ennuste

Nykyinen markkinakoko: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global fabry disease treatment market, and market shares of the segments. All the required percentage shares split and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.

Arvio ja ennusteet: Markkinoiden arvioinnissa ja ennusteissa painotettiin eri tekijöitä, kuten tekijöitä ja trendejä, rajoituksia ja sidosryhmien käytettävissä olevia mahdollisuuksia. Näiden tekijöiden analysoinnin jälkeen sovellettiin asiaankuuluvia ennustetekniikoita eli ylhäältä alas/alhaalta ylös -lähestymistapaa, jotta saatiin aikaan markkinaennuste vuodelle 2030 00 eri segmenteillä ja alasegmenteillä tärkeimmillä markkinoilla maailmanlaajuisesti. Markkinoiden koon arvioimiseksi käytetty tutkimusmetodologia sisältää:

  • The industry’s market size, in terms of revenue (USD) and the adoption rate of the fabry disease treatment market across the major markets domestically
  • Kaikki prosenttiosuudet, splitit ja markkinasegmenttien ja alasegmenttien erittelyt
  • Key players in the global fabry disease treatment market in terms of products offered. Also, the growth strategies adopted by these players to compete in the fast-growing market


Markkinoiden koon ja osuuden vahvistaminen

Perustutkimus: Tärkeimmillä alueilla suoritettiin perusteellisia haastatteluja tärkeimpien mielipidejohtajien (KOL) kanssa, mukaan lukien ylimmän tason johtajat (CXO/VP:t, myyntipäällikkö, markkinointipäällikkö, operatiivinen johtaja, aluejohtaja, maajohtaja jne.). Ensisijaiset tutkimustulokset koottiin sitten yhteen ja suoritettiin tilastollinen analyysi esitetyn hypoteesin todistamiseksi. Primääritutkimuksen panokset yhdistettiin toissijaisiin havaintoihin, jolloin tieto muutettiin käyttökelpoisiksi oivalluksiksi.

Ensisijaisten osallistujien jakautuminen eri alueilla

Fabry Disease Treatment Market
Fabry Disease Treatment Market

Markkinasuunnittelu

The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global fabry disease treatment market. Data was split into several segments & sub-segments post studying various parameters and trends in the areas of mode of administration, treatment, and regions in the global fabry disease treatment market.

The main objective of the Global Fabry Disease Treatment Market Study

The current & future market trends of the global fabry disease treatment market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:

  • Analyze the current and forecast market size of the fabry disease treatment market in terms of value (USD). Also, analyze the current and forecast market size of different segments and sub-segments
  • Segments in the study include areas of mode of administration, treatment, and regions
  • Define and analyze the regulatory framework for the fabry disease treatment industry.
  • Analysoi arvoketjua, joka liittyy erilaisten välittäjien läsnäoloon, sekä analysoi alan asiakkaiden ja kilpailijoiden käyttäytymistä.
  • Analyze the current and forecast market size of the fabry disease treatment market for the major region.
  • Suurimpia raportissa tutkittuja alueita ovat Aasia ja Tyynenmeren alue, Eurooppa, Pohjois-Amerikka ja muu maailma.
  • Company profiles of the fabry disease treatment market and the growth strategies adopted by the market players to sustain in the fast-growing market
  • Alan aluetason syvällinen analyysi

Voit myös ostaa osia tästä raportista. Haluatko tarkistaa osan viisaasti
hinta lista?